Fluimucil 200mg, 30 sachets, Zambon

Acetylcysteine belongs to a class of drugs called mucolytics and has mucolytic properties, acting on mucous secretion, decreasing its viscosity. Acetylcysteine is indicated as a mucolytic therapy in respiratory diseases (acute bronchitis, bronchiectasis, chronic bronchitis and its exacerbations, cystic fibrosis), characterized by dense and viscous hypersecretion.

Composition: One effervescent tablet contains: 600 mg of acetylcysteine, aspartame and flavorings. One packet of granules contains 100 or 200 mg of N-acetylcysteine, aspartame and flavorings.

How to use:

Always use Fluimucil 200 exactly as described in this leaflet or as told by your doctor or pharmacist. Talk to your doctor or pharmacist if you are not sure.
Acute bronchial and pulmonary disorders accompanied by bronchial secretion disorders:

Adults, adolescents and children over 6 years of age: the recommended dose is 600 mg of acetylcysteine per day, in three doses of 200 mg every 8 hours.
Children aged 2 to 6 years: the recommended dose is 400 mg of acetylcysteine per day, in two doses of 200 mg every 12 hours.
Pulmonary complications of cystic fibrosis:

Adults, adolescents and children over 6 years of age: the recommended dose is 200–400 mg of acetylcysteine every 8 hours.
Children between 2 and 6 years of age: the recommended dose is 200 mg of acetylcysteine every 8 hours.
The use of Fluimucil in age–appropriate concentrations is recommended.
Precautions:

Before using Fluimucil 200, talk to your doctor or pharmacist.
Mucolytic agents can induce airway obstruction in children under 2 years of age.
Due to the physiological characteristics of the airways in this age group, the ability to expectorate may be limited. That is why mucolytic agents should not be used in children under 2 years.

Due to the physiological characteristics of the airways in this age group, the ability to expectorate may be limited. Therefore, mucolytic agents should not be used in children under 2 years of age.
It is administered with caution when using the product in patients with peptic ulcer disease or a history of peptic ulcer, especially when administered concomitantly with other medicinal products that have a known effect on irritation of the gastric mucosa.
Patients suffering from asthma should be closely monitored during treatment. If acetylcysteine bronchospasm occurs, it should be discontinued immediately and appropriate therapeutic measures applied.
The administration of acetylcysteine, especially at the beginning of treatment, can fluidify and increase the volume of bronchial secretions. If the patient is unable to expectorate, postural drainage and bronchosuction should be performed.
Acetylcysteine may slightly affect histamine metabolism, so it should be used with caution when administered long-term to patients with histamine intolerance because symptoms of intolerance (headache, vasomotor rhinitis, pruritus) may occur.

Form of presentation: 30 envelopes.